GeneDx vs SOPHiA GENETICS (2026)
Both apply models to genomic interpretation and they sell to different parts of the same institution. GeneDx is a diagnostic service for rare disease, applying AI and expert variant interpretation to exome and genome sequencing, and it is measured on diagnostic yield, how many previously undiagnosed patients get an answer. SOPHiA is analysis infrastructure, a cloud native platform applying machine learning to call, annotate and interpret variants over sequencing a laboratory runs itself. So the question is whether you are sending cases out or building capability in. The exposure they share and neither resolves is ancestral representation: reference databases skew heavily European, variants of uncertain significance come back more often for everyone else, and neither vendor publishes yield or interpretation performance by ancestry. That is the number to demand from both.
- The clinical purpose is rare disease diagnosis rather than platform infrastructure, with variant interpretation combining models and expert review on exome and genome sequencing.
- The diagnostic yield question is the one that matters for this buyer, and a rare disease program is measured on how many undiagnosed patients get an answer rather than on how many samples it can process.
- For a pediatric or rare disease service, the interpretation depth is the product, and that is a different asset from the sequencing itself.
- The platform applies machine learning with patented algorithms to call, annotate and interpret variants across a hospital's own sequencing, so the institution keeps the workflow rather than sending it out.
- It is cloud native and sold as analysis infrastructure, which suits a laboratory building its own genomics capability rather than outsourcing cases.
- As a listed company it carries the financial disclosure obligations that a private counterpart does not, which is worth something when you are committing a laboratory workflow to a platform.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. GeneDx and SOPHiA GENETICS are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | GeneDx | SOPHiA GENETICS |
|---|---|---|
| Primary category | Diagnostics & Genomics | Diagnostics & Genomics |
| Founded | 2000 | 2011 |
| Headquarters | Gaithersburg, Maryland | Boston, Massachusetts |
| Website | genedx.com | sophiagenetics.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
GeneDx
-
Product / capability
GeneDx added Report Guide to its Provider Portal, which shows plain language guidance next to eligible exome and genome reports.
Source -
Product / capability
GeneDx introduced Easy Order at the 2026 American Academy of Pediatrics meeting.
Source -
Clinical evidence
GeneDx published results from a study at Seattle Children's supporting hospital wide adoption of rapid genomic sequencing rather than the usual narrow deployment in the NICU or a single specialty service.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Rare disease genomic diagnosis company (NASDAQ: WGS) in Gaithersburg, Maryland, running exome and genome sequencing in its own accredited laboratory and interpreting it with automation, machine learning and clinical scientists over GeneDx Infinity, its dataset of prior cases. Its published Multiscore model, a random forest gene ranker, placed the diagnostic gene in the top 20 in 93 percent of 9,989 cases (Human Genetics, 2026), and it acquired the AI interpretation company Fabric Genomics.
Source: AI Health Index, August 2026
Cloud genomics analysis company (NASDAQ: SOPH) based in Rolle, Switzerland and Boston. The SOPHiA DDM platform takes sequencing data a laboratory generates in house and calls, annotates and pre-classifies variants with in-house models (PEPPER for small variants, copy number, microsatellite instability and fusion callers, the GIInger deep learning score for genomic instability, and supervised pathogenicity pre-classification), with radiomics and multimodal modules alongside.
Source: AI Health Index, August 2026
Questions buyers ask
How do GeneDx and SOPHiA GENETICS work with the EHR?
In August 2026 GeneDx added Exome-to-Genome Reflex ordering inside Epic Aura, and the integration page links release notes for Aura updates.
With SOPHiA GENETICS, the platform page and flyer describe seamless, automated data transfer between technologies, EHR, LIMS and interpretation tools, and the company describes the platform as technology agnostic across sequencing instruments, which is what lets laboratories keep the sequencers they own. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are GeneDx and SOPHiA GENETICS priced and sold?
Tests can be billed to the patient's insurance, to an institutional account or to the patient as self-pay; GeneDx accepts commercial insurance, Medicaid, Medicare and Tricare and is in network with many plans, supports prior authorization, and offers financial assistance, sponsored testing programs and interest-free payment plans.
For SOPHiA GENETICS, the annual report states the company earns revenue on a pay-per-analysis basis, with application and product pricing, the access model and customer size also affecting revenue, and describes bundle solutions that pair the platform with third party products in the testing workflow. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do GeneDx and SOPHiA GENETICS handle patient data?
With GeneDx, the HIPAA notice allows research use when reviewed by an institutional review board or privacy board, and the Multiscore study was run on de-identified data under an IRB waiver of consent.
In SOPHiA GENETICS's case, the flyers describe how anonymized insights are shared, not what an institution can opt out of. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do GeneDx and SOPHiA GENETICS cover?
For GeneDx, the NICU use is supported by the SeqFirst-neo trial, the pediatric outpatient use by the American Academy of Pediatrics first-tier recommendation, and the online family route opened in August 2026 is limited to children with developmental delay, intellectual disability or epilepsy, subject to clinical appropriateness and state rules.
With SOPHiA GENETICS, the platform serves hospital and laboratory genomics in oncology (solid tumors, blood cancers, hereditary cancers, liquid biopsy, HRD) and rare and inherited disorders, with radiomics and multimodal modules for research, across more than 990 institutions. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
Both records depend on variant interpretation, where the central and largely unaddressed exposure is ancestral representation: reference databases and published variant evidence are drawn disproportionately from European ancestry populations, so variants of uncertain significance are returned more often for everyone else, and a diagnostic yield figure means little without the ancestry composition of the cohort behind it. Ask both vendors for yield by ancestry.
Genomic data is also permanent, cannot be revoked once disclosed, and carries implications for biological relatives who never consented, which makes the retention and secondary use terms especially consequential.